Drug intelligence / Profile preview

cyclic-di-gmp

Development stage
Preclinical
Lead developer
Novartis
Modality
Small Molecules
Administration
Intranasal, Intratumoral, Subcutaneous
01

Overview

Cyclic-di-GMP (c-di-GMP) is a naturally occurring cyclic dinucleotide that serves as a ubiquitous second messenger in bacteria and a potent modulator of the mammalian innate immune system. It acts as a direct ligand and agonist for the Stimulator of Interferon Genes (STING) receptor. Upon binding to STING, c-di-GMP triggers the TBK1-IRF3 signaling pathway, leading to the robust production of Type I interferons (IFN-α/β) and other pro-inflammatory cytokines. In the context of respiratory health, c-di-GMP has been shown to suppress Type 2 innate lymphoid cell (ILC2) activity and eosinophilic lung inflammation while promoting Type 1 immune responses. Due to its ability to enhance both cellular and humoral immunity, it is extensively investigated as a vaccine adjuvant and an immunotherapeutic agent for oncology and infectious diseases.

Other names
3',5'-cyclic diguanylic acidcyclic diguanylatec-di-GMP
02

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on cyclic-di-gmp.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclic-di-gmp.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call